The study aims (i) to evaluate changes in myocardial ischaemia on single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) after 2 years in a cohort of high-risk patients with diabetes without cardiac symptoms or known coronary artery disease (CAD) and (ii) to assess the value of baseline computed tomography coronary angiography (CTA)-derived coronary atherosclerosis parameters to predict changes in myocardial ischaemia.
Introduction
Cardiovascular death is the main cause of death in patients with diabetes mellitus (DM). 1 Moreover, patients with DM often have silent myocardial ischaemia on single-photon emission tomography (SPECT) myocardial perfusion imaging (MPI) and coronary artery disease (CAD) in an advanced stage on coronary computed tomography angiography (CTA). 2 -8 After 2-3 years of follow-up, a limited number of patients present with new ischaemia. 9 However, no clinical variables predictive of new ischaemia have yet been established. Potentially, atherosclerotic plaque characteristics on CTA could be associated with the onset of new ischaemia. Therefore, the aim of this study was to (i) evaluate changes in myocardial ischaemia after 2 years in a cohort of high-risk patients with diabetes without cardiac symptoms and (ii) to assess the value of baseline CTA-derived coronary atherosclerosis parameters to predict changes in myocardial ischaemia on SPECT MPI in these patients.
Methods Patients
The patient population consisted of 159 high-risk patients with diabetes without cardiac symptoms referred from a diabetic outpatient clinic for cardiovascular risk stratification as previously described. 10, 11 Inclusion criteria for the study were confirmed diagnosis of type 2 DM, normal resting electrocardiogram (ECG), and the absence of cardiac symptoms. Patients with known CAD or treated with anti-anginal medication were excluded, as well as patients with a previous stress test or coronary angiography. All patients underwent clinical evaluation, including laboratory testing, coronary artery calcium (CAC) scoring, coronary CTA, and SPECT MPI between May 2005 and January 2006. After 2 years of follow-up, SPECT MPI was repeated as prospectively scheduled to evaluate myocardial ischaemia as indicated in the guidelines that were applicable at that time. 12 Patients were treated according to the standard clinical care and based on test results. The patient's medical records were evaluated to assess whether the patient underwent coronary revascularization between the two SPECT MPI studies. Clinical data were prospectively entered into the departmental Cardiology Information System (EPD-Vision & , Leiden University Medical Center, the Netherlands) and retrospectively analysed. The Institutional Review Board of the Leiden University Medical Center approved this retrospective evaluation of clinically collected data and waived the need for written informed consent.
SPECT MPI Image acquisition
ECG-gated technetium-99 m sestamibi ( 99m Tc-sestamibi;1000MBq) SPECT MPI was performed using a 2-day stress and rest protocol. Patients had to refrain from caffeine-containing products 24 h before testing. Vasodilator stress was performed using adenosine (140 mg/kg/min, intravenous for 6 min) with simultaneous handgrip exercise. Blood pressure and 12-lead ECG were recorded during adenosine stress. SPECT imaging was performed, 120 min after injection of the radiopharmaceutical, using a triplehead SPECT gamma camera (GCA 9300/HG, Toshiba Corporation, Tokyo, Japan). Images were acquired using a circular 3608 orbit in 64 projections and 20 s per projection. 13 Attenuation correction was not performed.
Quantification of myocardial ischaemia
The SPECT MPI data sets were sent to an independent, dedicated core lab (INVIA, Ann Arbor, MI, USA), blinded of patients' history or scan order.
By using Corridor4DM (INVIA), myocardial perfusion and reversibility (ischaemia) were quantified as follows. 14, 15 First, the stress data set was normalized to the maximum pixel intensity within the myocardium; all values were multiplied by 100/value of the maximum pixel. Second, the rest data set was normalized in the same manner using the peak in the location of the peak intensity in the stress map. The extent of hypoperfusion in the stress study was expressed as a percentage of the entire left ventricle. Comparing the rest and the stress study allowed for assessment of reversibility by comparing the areas of hypoperfusion on the stress study with the same areas in the rest study; a ≥10% increase in tracer uptake was used to define reversibility. Reversibility was expressed as percentage of the entire left ventricle. Change in ischaemia was calculated as the differences in reversibility between the baseline and followup study. To facilitate the analysis, patients were stratified into two groups based on differences in reversibility between the baseline and follow-up study. Any increase in ischaemia was defined as progression, whereas a decrease in ischaemia was defined as regression.
Coronary computed tomography angiography Image acquisition
Patients were scanned with either a 64-slice CT scanner (Aquilion 64, Toshiba Medical System, Otowara, Japan) or a 320-row volumetric scanner (Aquilion ONE, Toshiba Medical System). Contraindications for CTA were (i) impaired renal function (glomerular filtration rate ,60 mL/min/1.73m
2 ), (ii) pregnancy, (iii) (supra-)ventricular arrhythmias, (iv) known allergy to contrast agent, and (v) severe claustrophobia. Non-contrast CT and contrast CTA were performed according to the standard clinical practice. Prior to CT examination, beta-blocking medication was administered if the heart rate was ≥65 bpm, unless contraindicated. Data sets were sent to a remote workstation for analysis.
Image analysis
Evaluation of the CTA was performed on a dedicated workstation (Vitrea FX, Vital Images, Minnetonka, MN, USA). For each patient, the Agatston CAC score was measured. Thereafter, the CTA data sets were evaluated for the presence, severity, and composition of coronary atherosclerosis as previously described. 16 In brief, each segment of the coronary tree was scored as normal (,30%), non-obstructive (30 -50%), or obstructive (≥50%) CAD. Coronary plaque composition was assessed as noncalcified, calcified, or mixed plaque. Per patient, the number of segments with atherosclerosis and the number of each type of plaque were assessed. Significant CAD was defined by the presence of a coronary lesion with ≥50% stenosis.
Statistical analysis
For reasons of uniformity summary, statistics for all continuous data are presented as mean + SD. Normality of the data was confirmed by comparing the histogram with a normal probability curve. Categorical data are presented as absolute numbers and percentages. First, clinical patient characteristics were compared between patients with and without ischaemia at baseline. Second, in a similar fashion, patients with and without ischaemia at follow-up were compared. Third, patients with and without progression of ischaemia were compared likewise. Thereafter, the CTA parameters of the extent, severity, and composition of coronary atherosclerosis were compared between all patient groups. Statistical significance was assessed using non-parametric tests for continuous data with a non-normal distribution and t-test for data with a normal distribution. Chi-square tests were applied to categorical data. All statistical tests were two sided, and a P-value of ,0.05 was considered statistically significant. All statistical analyses were performed with the SPSS software (Version 20.0, SPSS Inc., Chicago, IL, USA).
Results

Patient characteristics
The population consisted of 159 patients. In 36 patients, one of the two SPECT MPI studies was not performed (for logistical reasons). The data sets of the remaining 123 patients were sent to an independent core lab for quantification of myocardial ischaemia. In 16 patients, quantitative analysis could not be performed due to protocol violations or insufficient image quality. The results of 107 patients were available for analysis; 7 patients underwent planned revascularization between the two studies and were therefore excluded. The final patient cohort consisted of 100 patients. Table 1 demonstrates the baseline characteristics of the population. In total, 62 patients were male, half of the patients presented with hypertension or hypercholesterolaemia. Mean diabetes duration was 113 + 87 months. In Table 1 , the medical therapy at baseline is described. In total, 52 patients received statin therapy, 17 aspirin, and 31 ACE inhibitors. At follow-up, in 23 patients, statin therapy was added and 8 patients received additional ACE inhibitors. Aspirin was added in 22 patients. At follow-up, 19 patients received anti-angina medication (i.e. betablockers, calcium-antagonists, or nitrates).
SPECT MPI results
Median time between the two SPECT MPI studies was 30 [interquartile range (IQR) 27-33] months. As shown in Figure 1 , 20% of patients presented with ischaemia at baseline, without need of revascularization. Of these 20 patients, 7 (35%) patients still had ischaemia at follow-up, whereas 13 (65%) patients showed resolution of ischaemia and 4 showed progression of ischaemia at follow-up. Of the 80 patients without ischaemia at baseline, 65 (81%) had a normal study at follow-up and 15 patients (19%) presented with new ischaemia. with a normal baseline SPECT MPI, 19% of the patients presented with progression of ischaemia. In Table 1 , the baseline results stratified according to the presence of baseline ischaemia are demonstrated. Except for family history and low-density lipoprotein (LDL)-cholesterol, there were no significant differences between patients with or without myocardial ischaemia at baseline. In Table 2 , the difference in characteristics between patients with and without ischaemia at follow-up is shown. Remarkably, there were no significant differences between both patient groups. Table 3 summarizes the differences between baseline characteristics between patients with and without progression of ischaemia. DM duration was significantly longer among patients who showed progression of ischaemia (180 + 97 vs. 135 + 83 months, P ¼ 0.049). The remaining baseline characteristics were comparable between patients with and without progression of ischaemia. At follow-up, five patients presented with onset of chest pain, of which one had progression of ischaemia and four presented without new ischaemia. Of the 19 patients in whom anti-anginal medication was added, 2 presented with progression of ischaemia (P ¼ 0.295). There was no relation between the onset of symptoms and new ischaemia or progression of ischaemia.
CTA results
Ninety-three of the 100 patients underwent coronary CTA and 98 patients CAC scoring. The median time between the first SPECT MPI and CTA was 22 (IQR 4-46) days. In Table 4 , the CTA results are demonstrated, stratified according to the presence of baseline and follow-up ischaemia. A comparison was made for the presence, extent, and composition of coronary atherosclerosis on CTA. For all parameters, there were no significant differences between patients with and without ischaemia at baseline. Similarly, no differences could be demonstrated between patients with and without ischaemia at follow-up or between patients with and without progression of ischaemia. Overall, 24 (26%) patients presented with obstructive CAD on CTA (of note: patients who underwent revascularization between the two SPECT MPI studies were excluded). In patients with ischaemia at baseline, more had obstructive CAD (33 vs. 24%, P ¼ 0.476) but these differences were not significant. These patients also had a higher mean CAC score [19 (IQR 0-115) vs. 4 (IQR 0-101), P ¼ 0.390], but the difference was not statistically different. In patients presenting with progression of ischaemia, obstructive CAD occurred more often (35 vs. 24%, P ¼ 0.546) and CAC scores were slightly higher [16 (IQR 0-81) vs. 4 (IQR 0-112), P ¼ 0.408], but these differences were also not significant.
Discussion
The present study demonstrated a low rate of progression of ischaemia after 2 years in high-risk patients with diabetes without cardiac Abbreviations and definitions as in Table 1 .
Bold values have a significant P-value (,0.05).
symptoms. Moreover, no relation between atherosclerosis parameters on CTA and changes of ischaemia was observed. Previous studies have investigated the role of screening with SPECT MPI for silent ischaemia in asymptomatic diabetic patients. 17 Most importantly, in the Detection of Ischaemia in Asymptomatic Diabetics (DIAD) study, 1123 diabetic patients without any suspicion of CAD were randomized between screening with SPECT MPI and no screening. 18 Of the 522 patients who underwent SPECT MPI, 133 (22%) presented with an abnormal study, the majority (73%) of which were regional perfusion abnormalities. 9 Except for gender, diabetes duration, and heart rate response to Valsalva (performed as part of cardiac autonomic function testing), no clinical characteristics or laboratory markers could accurately predict the presence of silent ischaemia in these patients. Second, Lorenzo et al. 19 included 180 asymptomatic diabetic patients who underwent SPECT MPI and were followed for a mean period of 36 months. In total, 46 patients (26%) of the patients presented with an abnormal MPI. No differences in characteristics were observed between patients with and without myocardial ischaemia. However, at present, only one study has focused on progression of ischaemia in these patients. In DIAD-2, 358 of the initial 522 patients underwent a second SPECT MPI study to evaluate the change in myocardial perfusion after a 3-year interval. 9 Similar to the present study, of the 71 (20%) patients who presented with an abnormal SPECT MPI study at baseline, 56 (79%) showed resolution of ischaemia after 3 years, whereas only a limited number of patients (10%) with a normal baseline examination presented with new ischaemia. Likely this resolution of ischaemia was caused by intensified medical therapy after recommendations in the American Diabetes Association (ADA) guidelines. 20 Similarly, in the present report, medical therapy was intensified at follow-up. However, no relation between added antianginal medication and ischaemia progression could be established.
Compared with the present report, in DIAD-2, the value of clinical characteristics to predict the risk of new ischaemia was limited. Only peripheral vessel disease (PVD) and elevated LDL-cholesterol levels were associated with new onset of ischaemia. Presumably, the relative low rate of progression of ischaemia is caused by accurate medical therapy. If these diabetic patients are treated according to the guidelines based on the outcomes of testing, the clinical follow-up is prosperous. It seems that medical treatment outweighs the potential negative effect of other clinical characteristics. It would however have been unethical to refrain patients from appropriate medical therapy.
In this report, there was no significant difference between the median CAC score in patients with and without baseline ischaemia. In contrast, Anand et al. 21 showed a significant association between the CAC score and myocardial ischaemia in 510 asymptomatic diabetic patients. MPI was performed in all patients with a CAC score .100 and in a random sample of patients with a CAC score ≤100. The CAC score was significantly associated with the presence of myocardial ischaemia. Of particular interest, all patients with a CAC score ≤10 presented with a normal SPECT MPI. CTA and ischaemia on SPECT MPI, both in patients with stable angina and asymptomatic diabetic patients. 11, 22 However, for the present study, it was hypothesized that CTA could be able to identify different coronary atherosclerotic plaque characteristics that could predict changes in myocardial ischaemia on SPECT MPI. The relation between coronary plaque type and the presence of myocardial ischaemia has previously been studied. 23 The underlying pathophysiological relation between coronary plaque composition and myocardial ischaemia is unknown. Possible, mixed plaques with a relatively large plaque burden are prone to rupture, causing myocardial ischaemia, whereas the more advanced stage of calcified plaque is relatively stable. Especially in a patient without baseline ischaemia, rupture of a haemodynamically nonsignificant plaque could cause onset of ischaemia. However, the relation between CTA atherosclerosis parameters and progression of atherosclerosis has not been described earlier. Moreover, in the present study, no association could be established between CTA coronary atherosclerosis and changes in myocardial ischaemia. There was no significant difference in the different plaque types between patients with and without onset of new ischaemia or progression of ischaemia. Nor could a difference in the presence of non-obstructive CAD between both patient groups be established. Moreover, the CAC score was similar in both groups. The relative disagreement between atherosclerosis on CTA and ischaemia on SPECT MPI could be caused by the fact that the two different modalities evaluate different manifestations of CAD. CTA only allows assessment of coronary artery stenosis in the major epicardial coronary arteries. On the other hand, SPECT MPI visualizes perfusion defects, which could be caused by either stenosis in a major epicardial coronary artery and/or by microvascular disease and endothelial dysfunction. However, it is well known that especially in diabetic patients, microvascular disease plays an important role in the onset of myocardial ischaemia. 6 
Limitations
Some limitations need to be considered. First, a limited number of patients was included. Second, patients who underwent revascularization were excluded, which may have affected results. And furthermore, additional SPECT parameters such as left ventricular ejection fraction, transient ischaemic dilatation, or ECG abnormalities were not incorporated in the current analysis.
Conclusions
The rate of progression of ischaemia in high-risk patients with diabetes without cardiac symptoms is limited. Few patients presented with new ischaemia, whereas some patients showed resolution of ischaemia. Atherosclerosis parameters on CTA were not predictive of new-onset ischaemia or progression of ischaemia.
Baseline characteristics, CAC score, or atherosclerosis parameters on CTA were not predictive of the onset of new ischaemia or were not correlated with progression of ischaemia.
